# Actionable Biomarkers and Targeted Therapy Mapping
# Generated for Clinical Trial Matching RAG System
# Last Updated: 2025-11-06

This document provides comprehensive biomarker-to-therapy mappings for precision oncology.
Used to enhance trial matching by identifying biomarker-driven therapeutic opportunities.

================================================================================
## PIK3CA MUTATIONS
================================================================================

**Mutation Types:**
- Hotspot mutations: E542K, E545K, H1047R, H1047L, E726K
- Pathogenic across multiple cancer types
- Activates PI3K/AKT/mTOR pathway

**Approved Targeted Therapies:**
- Alpelisib (Piqray) + fulvestrant: HR+ HER2- breast cancer with PIK3CA mutation
  - FDA approved 2019
  - Requires documented PIK3CA mutation by FDA-approved test

**Active Clinical Trial Landscape:**
- Phase 2/3 trials: GDC-0077, LOXO-783 (next-generation PI3K inhibitors)
- Combination trials: PI3K inhibitor + endocrine therapy
- Basket trials: Multiple solid tumors with PIK3CA mutations
- Common eligibility: Prior systemic therapy, ECOG 0-2, measurable disease

**Cancer Types with PIK3CA-Directed Trials:**
- Breast cancer (most common, ~40% HR+ tumors)
- Cervical cancer (15-30% harbor PIK3CA mutations)
- Endometrial cancer (30-50% mutation rate)
- Head and neck squamous cell (10-15%)
- Colorectal cancer (10-20%)

**Typical Trial Eligibility Criteria:**
- Documented PIK3CA mutation (E542K, E545K, or H1047R preferred)
- Prior standard therapy completion/progression
- ECOG performance status 0-2
- Adequate organ function (hyperglycemia monitoring required)
- Exclusion: Uncontrolled diabetes (PI3K inhibitors cause hyperglycemia)

**Key Trials to Reference:**
- SOLAR-1: Alpelisib + fulvestrant in HR+ breast cancer
- BYLieve: Alpelisib in PIK3CA-mutant breast cancer
- NCT02437318: Alpelisib basket trial in solid tumors

================================================================================
## PD-L1 EXPRESSION
================================================================================

**Testing Methods:**
- Combined Positive Score (CPS): (PD-L1+ cells / total tumor cells) × 100
- Tumor Proportion Score (TPS): % of tumor cells with PD-L1 expression
- Different cutoffs for different indications

**Approved Immunotherapy by PD-L1 Status:**

**CPS ≥1:**
- Pembrolizumab: Cervical cancer (2nd line)
- Pembrolizumab: Gastric/GEJ cancer (1st line + chemotherapy)
- Pembrolizumab: HNSCC (1st line monotherapy or + chemo)

**CPS ≥10:**
- Pembrolizumab: Cervical cancer (1st line + chemotherapy or bevacizumab)
- Pembrolizumab: HNSCC (1st line monotherapy)

**TPS ≥50%:**
- Pembrolizumab: NSCLC (1st line monotherapy)
- Cemiplimab: NSCLC (1st line monotherapy)

**TPS ≥1%:**
- Pembrolizumab: NSCLC (1st line + chemotherapy)
- Atezolizumab: NSCLC (various combinations)

**Clinical Trial Landscape:**
- Combination trials: PD-1/PD-L1 inhibitor + chemotherapy
- Dual checkpoint blockade: PD-1 + CTLA-4 (ipilimumab)
- Novel combinations: PD-1 + targeted therapy (VEGF, PARP, etc.)

**Common Eligibility Patterns:**
- PD-L1 CPS ≥1 (more permissive trials)
- PD-L1 CPS ≥10 (enriched populations)
- Some trials are PD-L1 unselected (basket approach)
- ECOG 0-1 (occasionally 0-2 for later-line trials)
- No active autoimmune disease (relative contraindication)

================================================================================
## EGFR MUTATIONS (Non-Small Cell Lung Cancer)
================================================================================

**Common Activating Mutations:**
- Exon 19 deletions (~45% of EGFR mutations)
- L858R point mutation (~40% of EGFR mutations)
- Exon 20 insertions (~5%, historically resistant)
- Uncommon mutations: G719X, L861Q, S768I

**Resistance Mutations:**
- T790M: Most common acquired resistance to 1st/2nd gen EGFR TKIs
- C797S: Resistance to osimertinib (3rd gen)

**FDA-Approved Targeted Therapies:**

**1st Line EGFR+ NSCLC:**
- Osimertinib (Tagrisso): Preferred, covers T790M
- Erlotinib, gefitinib, afatinib, dacomitinib (alternative options)

**T790M+ After 1st/2nd Gen TKI:**
- Osimertinib

**Exon 20 Insertions:**
- Amivantamab (bispecific antibody)
- Mobocertinib (oral TKI)

**Clinical Trial Landscape:**
- 4th generation EGFR TKIs (C797S resistance)
- EGFR TKI + chemotherapy combinations
- EGFR TKI + antiangiogenic therapy
- Novel exon 20 insertion inhibitors

**Typical Eligibility:**
- Documented EGFR mutation (specific variants required)
- Treatment-naive OR progression on prior EGFR TKI
- ECOG 0-1 (occasionally 0-2)
- Brain metastases: Often allowed if treated and stable
- Prior treatment lines: Varies by trial design

================================================================================
## BRCA1/BRCA2 Mutations
================================================================================

**Germline vs Somatic:**
- Germline: Hereditary breast/ovarian cancer syndrome
- Somatic: Tumor-acquired mutations
- Both qualify for PARP inhibitor trials

**FDA-Approved PARP Inhibitors:**

**Ovarian Cancer:**
- Olaparib (Lynparza): Germline or somatic BRCA, maintenance and treatment
- Rucaparib (Rubraca): BRCA-mutant, 2nd line maintenance
- Niraparib (Zejula): Maintenance regardless of BRCA status

**Breast Cancer:**
- Olaparib: Germline BRCA, HER2- metastatic breast cancer
- Talazoparib: Germline BRCA, HER2- metastatic breast cancer

**Prostate Cancer:**
- Olaparib: mCRPC with HRR gene alterations (BRCA1/2, ATM, etc.)
- Rucaparib: mCRPC with BRCA mutations

**Pancreatic Cancer:**
- Olaparib: Germline BRCA-mutant, maintenance after platinum

**Clinical Trial Landscape:**
- PARP inhibitor combinations (+ immunotherapy, + antiangiogenics)
- Novel PARP inhibitors
- DNA damage response pathway inhibitors (ATR, CHK1)
- Platinum chemotherapy trials (BRCA-mutant tumors are platinum-sensitive)

**Eligibility Patterns:**
- Documented germline or somatic BRCA1/2 mutation
- Prior platinum exposure (sometimes required, sometimes excluded)
- HRD testing (homologous recombination deficiency) increasingly used
- ECOG 0-2 typical

================================================================================
## KRAS Mutations
================================================================================

**Mutation Landscape:**
- Most common oncogene in cancer (~30% of all cancers)
- Historically "undruggable" - changed in 2021

**KRAS G12C Specific:**
- ~13% of NSCLC
- ~3-5% of colorectal cancer
- Target of covalent inhibitors

**FDA-Approved Therapies:**
- Sotorasib (Lumakras): KRAS G12C+ NSCLC, 2nd line
- Adagrasib (Krazati): KRAS G12C+ NSCLC, 2nd line

**Clinical Trial Landscape:**
- KRAS G12C inhibitors: Sotorasib, adagrasib, JDQ443
- Combination trials: KRAS G12C inhibitor + chemotherapy, + immunotherapy, + targeted therapy
- Pan-KRAS inhibitors (G12D, G12V, etc.) - early phase
- KRAS G12D inhibitors: MRTX1133 (preclinical/phase 1)

**Eligibility for KRAS G12C Trials:**
- Documented KRAS G12C mutation (specific variant)
- Prior platinum-based chemotherapy (NSCLC)
- ECOG 0-1
- Brain metastases: Often allowed if stable
- No prior KRAS G12C inhibitor (for first-line G12C trials)

**Other KRAS Mutations:**
- G12D, G12V: Pan-KRAS trials, investigational
- Usually treated with standard chemotherapy in practice
- Clinical trials exploring indirect KRAS pathway inhibition (SHP2 inhibitors, etc.)

================================================================================
## HER2 (ERBB2) Alterations
================================================================================

**Types of HER2 Alterations:**
- Amplification (most common in breast, gastric cancer)
- Overexpression (IHC 3+)
- Mutations (point mutations, exon 20 insertions in lung cancer)

**HER2-Positive Breast Cancer (IHC 3+ or ISH+):**
- Trastuzumab + chemotherapy (1st line standard)
- Pertuzumab + trastuzumab + chemo (neoadjuvant/metastatic)
- T-DM1 (trastuzumab emtansine): ADC for 2nd line
- T-DXd (trastuzumab deruxtecan): ADC for 3rd line
- Tucatinib + trastuzumab + capecitabine (brain mets)
- Neratinib, lapatinib (TKI options)

**HER2-Low Breast Cancer (IHC 1+ or 2+/ISH-):**
- T-DXd: Recently approved for HER2-low metastatic breast cancer

**HER2+ Gastric/GEJ Cancer:**
- Trastuzumab + chemotherapy (1st line)
- T-DXd (2nd line and beyond)

**HER2 Mutations (NSCLC):**
- Exon 20 insertions: Similar to EGFR exon 20
- T-DXd: Active in HER2-mutant NSCLC
- Poziotinib: Investigational

**Clinical Trial Landscape:**
- Novel ADCs (antibody-drug conjugates)
- TKIs for HER2 mutations
- Bispecific antibodies (HER2-targeted)
- Combinations: HER2 therapy + immunotherapy

**Eligibility Patterns:**
- HER2 status required (IHC, ISH, or NGS)
- Prior HER2-directed therapy (for later-line trials)
- LVEF monitoring (cardiac toxicity risk)
- ECOG 0-2 typical

================================================================================
## MSI-H / dMMR (Microsatellite Instability)
================================================================================

**Definition:**
- MSI-H: Microsatellite instability-high
- dMMR: Deficient mismatch repair
- Caused by loss of MLH1, MSH2, MSH6, PMS2 proteins

**Prevalence:**
- Colorectal cancer: ~15% (sporadic and Lynch syndrome)
- Endometrial cancer: ~30%
- Gastric cancer: ~10%
- Other solid tumors: 1-5%

**FDA-Approved Immunotherapy:**
- Pembrolizumab: MSI-H/dMMR solid tumors (tumor-agnostic, 2017)
- Nivolumab: MSI-H/dMMR colorectal cancer (2nd line)
- Nivolumab + ipilimumab: MSI-H/dMMR colorectal cancer

**Why Immunotherapy Works:**
- High tumor mutational burden (TMB)
- Neoantigen generation
- Highly immunogenic tumors

**Clinical Trial Landscape:**
- Checkpoint inhibitors in earlier lines (neoadjuvant, adjuvant)
- Dual checkpoint blockade optimization
- Chemotherapy-free regimens

**Eligibility:**
- Documented MSI-H or dMMR status (IHC or PCR)
- ECOG 0-1 typically
- Prior treatment varies (1st line trials emerging)
- Often tumor-agnostic basket trials

================================================================================
## BRAF V600E Mutations
================================================================================

**Prevalence:**
- Melanoma: ~50%
- Colorectal cancer: ~10%
- Thyroid cancer (papillary): ~45%
- NSCLC: ~2%
- Hairy cell leukemia: >95%

**FDA-Approved Targeted Therapies:**

**Melanoma:**
- Dabrafenib + trametinib (BRAF + MEK inhibitor combination)
- Vemurafenib + cobimetinib
- Encorafenib + binimetinib

**BRAF V600E Colorectal Cancer:**
- Encorafenib + cetuximab (± binimetinib)

**BRAF V600E NSCLC:**
- Dabrafenib + trametinib

**Thyroid Cancer:**
- Dabrafenib + trametinib (anaplastic, V600E+)

**Clinical Trials:**
- BRAF + MEK + immunotherapy (triplet combinations)
- Novel BRAF inhibitors (class II, paradox breakers)
- BRAF V600K and non-V600 mutations (investigational)

**Eligibility:**
- Documented BRAF V600E (or V600K for some trials)
- ECOG 0-1
- Brain metastases: Often allowed in melanoma trials
- Prior immunotherapy: May be required for melanoma trials

================================================================================
## ALK Rearrangements (NSCLC)
================================================================================

**Prevalence:**
- NSCLC: ~5% (enriched in never/light smokers, adenocarcinoma)
- Mutually exclusive with EGFR, KRAS

**FDA-Approved ALK TKIs (chronological order):**
1. Crizotinib (1st gen, 2011)
2. Ceritinib (2nd gen)
3. Alectinib (2nd gen, now preferred 1st line)
4. Brigatinib (2nd gen)
5. Lorlatinib (3rd gen, brain penetrant)

**Resistance Patterns:**
- ALK mutations: G1202R, L1196M, etc.
- Bypass pathways: EGFR, KIT, IGF-1R activation
- Histologic transformation

**Clinical Trial Landscape:**
- Next-generation ALK inhibitors
- ALK TKI + chemotherapy combinations
- Brain metastasis-focused trials (CNS penetration)

**Eligibility:**
- ALK rearrangement by FISH, IHC, or NGS
- Treatment-naive OR progression on prior ALK TKI
- ECOG 0-2
- Brain metastases: Commonly allowed
- Prior lines: Varies by trial

================================================================================
## ROS1 Rearrangements
================================================================================

**Prevalence:**
- NSCLC: ~1-2%
- Similar patient population to ALK+ (never-smokers, adenocarcinoma)

**FDA-Approved Therapies:**
- Crizotinib (ALK/ROS1 dual inhibitor)
- Entrectinib (ROS1/NTRK/ALK multi-kinase inhibitor)
- Repotrectinib (recently approved, 2023)

**Clinical Trials:**
- Novel ROS1 inhibitors (lorlatinib, taletrectinib)
- Brain metastasis trials

**Eligibility:**
- ROS1 rearrangement documented
- Similar to ALK trials
- Small patient population → often included in basket trials

================================================================================
## NTRK Fusions (Tumor-Agnostic)
================================================================================

**Prevalence:**
- Overall: <1% of solid tumors
- Enriched in: Secretory breast carcinoma, infantile fibrosarcoma, some thyroid cancers

**FDA-Approved TRK Inhibitors:**
- Larotrectinib (Vitrakvi): Tumor-agnostic, 2018
- Entrectinib (Rozlytrek): Tumor-agnostic, 2019

**Clinical Trials:**
- Next-generation TRK inhibitors (resistance mutations)
- Pediatric trials (higher prevalence)

**Eligibility:**
- NTRK1, NTRK2, or NTRK3 fusion
- Tumor-agnostic: Any solid tumor
- Prior treatment required in most cases
- ECOG 0-2

================================================================================
## Tumor Mutational Burden (TMB-H)
================================================================================

**Definition:**
- TMB: Number of mutations per megabase
- TMB-H: ≥10 mutations/Mb (FDA cutoff for pembrolizumab approval)

**FDA Approval:**
- Pembrolizumab: TMB-H solid tumors (2020, tumor-agnostic)
- Controversial approval (withdrawn in some regions due to limited benefit)

**Clinical Trials:**
- Checkpoint inhibitor combinations
- TMB as enrichment biomarker

**Eligibility:**
- TMB ≥10 mut/Mb (or trial-specific cutoff)
- Comprehensive genomic profiling required
- Prior treatment typically required

================================================================================
## Summary: Common Eligibility Themes Across Biomarker Trials
================================================================================

**General Patterns:**

1. **Biomarker Documentation Requirements:**
   - CLIA-certified lab testing
   - Specific assay platforms may be required (FoundationOne, Guardant360, etc.)
   - Fresh vs archival tissue specifications

2. **Performance Status:**
   - Early phase (Phase 1): ECOG 0-1
   - Later phase (Phase 2/3): ECOG 0-2 (occasionally)

3. **Brain Metastases:**
   - Increasingly allowed if treated and stable
   - Targeted therapy trials more permissive than chemotherapy trials

4. **Prior Treatment:**
   - 1st line trials: Treatment-naive
   - 2nd line+: Progression on standard therapy
   - Basket trials: Often later-line, heavily pretreated

5. **Organ Function:**
   - Adequate bone marrow (ANC >1.5, platelets >100k typical)
   - Hepatic function (bilirubin <1.5x ULN, AST/ALT <3x ULN)
   - Renal function (CrCl >30-60 mL/min depending on drug)

6. **Exclusions:**
   - Active untreated brain metastases
   - Uncontrolled intercurrent illness
   - Prior therapy with same class (for targeted trials)
   - Pregnancy/nursing

This document serves as a knowledge base for the RAG system to match patients with
biomarker-selected trials more accurately.
